NSCLC Drug Universe Expands: Genentech's Alecensa OK'd
This article was originally published in Scrip
Executive Summary
The universe seems to be working this year in favor of patients with non-small-cell lung cancer (NSCLC) – with a lot of help from drug makers and the FDA's Office of Hematology and Oncology Products.
You may also be interested in...
Zykadia Challenged As Roche’s Alecensa Gets EU Nod
Roche’s Alecensa gets EU nod for second-line use in ALK+ non-small cell lung cancer patients – but first-line data in 2017 will be vital.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.